A BRIGHT FUTURE Annual Report and Accounts 2017 Nanoco Group plc – Annual Report and Accounts 2017 Forward-looking statements The disclosures in this Annual Report for Nanoco Group plc  ("the Company") and its subsidiaries ("Nanoco" or "the  Group") contain certain forward‑looking statements. Although the Board believes that the expectations  reflected in these forward‑ looking statements are  reasonable, it can give no assurance that these  expectations will arise. Because the expectations  are subject to risks and uncertainties, actual results may  vary significantly from those expressed or implied by the  forward‑ looking statements based upon a number of  factors. Such forward‑ looking statements include  the statements under "Outlook", prospects and the  commercial success of our CFQD ®  applications and  other existing or future revenue‑ generating sources,  risks related to the Group’s ability or that of its  sub‑ contractors and partners to manufacture products  on a large scale or at all, risks related to the Group’s  and its marketing partners’ ability to market products  on a large scale or expand market share in the face of  changes in customer requirements, competition and  regulatory and technological change, risks related to  the ownership and use of intellectual property, and  risks related to the Group’s ability to manage growth. Nanoco undertakes no obligation to revise or update  any forward‑ looking statement to reflect events or  circumstances after the date of the Annual Report. Nanoco Group plc is a world leader in the research, development  and large-scale manufacture of cadmium and heavy-metal-free  quantum dots and semiconductor nanoparticles. Strategic report Highlights 01 At a glance 02 Chairman’s statement 04 Chief Executive Officer’s statement 06 Our business model 10 Our markets 12 Our strategy 14 Our key performance indicators 16 Principal risks and uncertainties 18 Viability statement 20 Financial review 22 Sustainability 25 Corporate governance Board of Directors 32 Corporate governance statement 34 Nominations Committee report 37 Audit Committee report 38 Remuneration Committee report 41 Directors’ remuneration report 43 Directors’ report 60 Statement of Directors’ responsibilities 64 Financial statements Independent auditor’s report 65 Consolidated statement  of comprehensive income 71 Consolidated statement of changes in equity 72 Company statement of changes in equity 72 Statement of financial position 73 Cash flow statements 74 Notes to the financial statements 75 Investor information IBC A BRIGHT FUTURE... THE FUTURE IS CFQD® Find out more about us online at   STRATEGIC REPORT CORPORATE GOVERNANCE FINANCIAL STATEMENTS 01 Nanoco Group plc – Annual Report and Accounts 2017 HIGHLIGHT S Display  • Hybrid commercial model in display established: direct sales of own manufactured   product and multiple non-exclusive licences  • Ten-fold increase in manufacturing capacity at Runcorn and reduction in product costs  • First commercial sales orders received  • Substantial pipeline of commercial opportunities – focused   on television and monitor projects with near term potential  • Signed development and commercialisation deal  with Kyulux focused on CFQD/OLED hybrid display  • Operating cost base reduced significantly Solar  • Decision taken to divest and process ongoing Life sciences and Lighting  • New grant awarded for work on pancreatic cancer and excellent progress   made in research in medical applications Financial results  • Revenue and other operating income for the year was £1.6 million (2016: £0.8 million)   and the loss after tax was £9.1 million (2016: £10.6 million)  • Cash and cash on deposit at 31 July 2017 was £5.7 million (2016: £14.5 million) Post balance sheet events  • Net proceeds of £8 million following a placing in November 2017 significantly   strengthens cash balance and removes immediate going concern issues  • Successful exhibition of televisions containing Nanoco Fine Color Film TM  at Touch Taiwan   • In September 2017, a Commercial Supply and License Agreement was finalised with  a US corporation in the field of medical devices for the treatment of pain, soft tissue  injury and dermatological conditions such as acne and skin anti-ageing 2017 £5.7m 2017 £1.3m 2016 £14.5m 2016 £0.5m Cash and short-term deposits Revenue * “Total billings” is the sum of invoices raised for revenue, other operating income   and deferred revenue (see page 23 for reconciliation to income statement). 2017 £9.1m 2017 £1.1m 2016 £10.6m 2016 £1.9m Loss after tax Total billings* 02 Strategic report WHAT WE DO ILLUMINATING  OUR TECHNOLOGY AT A GL ANCE LIGHTING Direct sales of own manufactured product Specialised lighting focus  Horticulture  Phototherapy We are focused on continually developing and scaling up CFQD ®  quantum dots that are fit for purpose  across large addressable markets. Our ability to innovate keeps us at the cutting edge of technology..